4OD Stock Overview
Odonate, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Odonate, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.23 |
| 52 Week High | US$2.90 |
| 52 Week Low | US$0.88 |
| Beta | 0.062 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -55.44% |
| 3 Year Change | -95.57% |
| 5 Year Change | n/a |
| Change since IPO | -93.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4OD | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.1% | -1.9% |
| 1Y | -55.4% | -29.2% | 1.1% |
Return vs Industry: 4OD underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: 4OD underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 4OD volatility | |
|---|---|
| 4OD Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4OD has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 4OD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 145 | Kevin Tang | www.odonate.com |
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.
Odonate, Inc. Fundamentals Summary
| 4OD fundamental statistics | |
|---|---|
| Market cap | €43.79m |
| Earnings (TTM) | -€101.27m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs 4OD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4OD income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$102.07m |
| Earnings | -US$102.07m |
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.47 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 4OD perform over the long term?
See historical performance and comparison